ALACHUA, Fla.--(BUSINESS WIRE)--RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, reported operating results for the third quarter of 2011 as follows:
Quarterly Highlights: •Achieved quarterly revenues of $42.3 million. •Achieved quarterly net income of $2.7 million, or $0.05 per fully diluted share. •Achieved quarterly revenues of $12.1 million in the U.S. direct distribution organization, a 7 percent increase over the third quarter of 2010. The U.S. direct distribution organization includes sports medicine and some bone graft substitute/general orthopedic (BGS/GO) implants.
